Glycoprotein IIb/IIIa inhibitors: An update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy

Keyphrases

• Mechanism of Action 100%
• Testing Method 100%
• Antiplatelet 100%
• GPIIbIIIa 100%
• Glycoprotein IIb/IIIa Inhibitors 100%
• Functional Testing 100%
• Platelet Aggregation 40%
• Integrin 40%
• Thrombosis 20%
• Plasma Membrane 20%
• Bleeding Complications 20%
• Percutaneous Coronary Intervention 20%
• Bleeding 20%
• Clinical Benefit 20%
• Tirofiban 20%
• Laboratory Monitoring 20%
• Thrombus Formation 20%
• Clinical High Risk 20%
• Large Families 20%
• Platelet Inhibition 20%
• Adverse Events 20%
• Adhesion Molecules 20%
• Safety Profile 20%
• Antiplatelet Therapy 20%
• Primary Function 20%
• Antithrombotic Agents 20%
• Glycoprotein IIb-IIIa 20%
• Large-scale Clinical Trial 20%
• Good Safety 20%
• Eptifibatide 20%
• Abciximab 20%
• Clinical Outcomes 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Antiplatelet 100%
• Fibrinogen Receptor 100%
• Integrin 66%
• Clinical Trial 33%
• Thrombus 33%
• Receptor 33%
• Bleeding 33%
• Adverse Event 33%
• Anticoagulant Agent 33%
• Tirofiban 33%
• Thrombosis 33%
• Eptifibatide 33%
• Abciximab 33%
• Cell Adhesion Proteins 33%